Patients to benefit from innovative new drugs in Northern Ireland

The drugs which are evaluated under the Highly Specialised Technology Programme of the National Institute for Health and Care Excellence (NICE), are to be made available to patients who have very rare conditions including atypical Haemolytic Uraemic Syndrome, mucopolysaccharidosis type IVa and Duchenne muscular dystrophy caused by a nonsense mutation, the Health Minister Michelle O’Neill announced.

Eligible patients in the north of Ireland will now receive innovative new drugs for the treatment of very rare conditions reports the Northern Irish Department for Health.

To read more about this, please click here.

Tagged with

Published 20. July 2016 in News UK